Samsara BioCapital — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Sutro BioPharma, Inc.NASDAQ: STROMay 2018
Clinical-stage company developing next generation antibody drug conjugates for cancer treatment using proprietary cell-free protein manufacturing technology.
BiotechSouth San Francisco, US
Joseph Lobacki(Director)Daniel Janney(Director)Armen Shanafelt(Director)Virgil Bryan Lawlis(Director)John G. Freund(Director)William J. Newell(Executive Officer, Director)
Board seatMichael Bryan Dybbs· per SEC Form D
Syros Pharmaceuticals, Inc.Jan 2018SEC filingmedium confidence
Cambridge, US
Board seatSrinivas Akkaraju· per SEC Form D · $11.4M raise · filed Feb 2018
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.